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Introduction {#sec1}
============

The dynamic interplay between pro- and antiapoptotic members of the BCL-2 family dictates life and death decisions. Activation of the proapoptotic BCL-2 proteins, BAK and BAX (the effectors), represents the pivotal step toward apoptosis by mediating mitochondrial outer membrane permeabilization (MOMP) ([@bib6; @bib38]). Despite their essential role in apoptosis, how effectors are activated by other BCL-2 family members remains controversial ([@bib18]). According to the indirect model, antiapoptotic BCL-2 proteins sequester effectors to block their proapoptotic function. BH3-only proteins can displace BAK or BAX from their antiapoptotic counterparts, thereby facilitating their oligomerization and subsequent MOMP ([@bib37]). A competing direct activation model proposes that effector function is triggered by activator BH3-only proteins, such as BIM and tBID ([@bib14; @bib28; @bib36]).

Although the underlying mechanism of activation remains unclear, effectors undergo major structural reorganizations in order to convert the monomeric, globular, closely packed protein into a highly ordered, multimeric mitochondrial permeabilizing pore. The association of BAK with antiapoptotic BCL-2 family members, as predicted by the indirect model, occurs through the canonical BH3:groove interface ([@bib29; @bib37]). Because the BH3 domain is occluded in inactive BAK, exposure of the BH3 domain, which coincidentally results in the opening of the hydrophobic binding groove (BH1--BH3 domains), has to precede BCL-X~L~ association ([@bib21]). This conformational change may be induced by direct association with activators either through the canonical BH3:groove interface or the BH3 trigger site (a hydrophobic cleft opposite the canonical groove formed by α1 and α6 helices; [@bib7; @bib19; @bib22]). The resulting conformation can then engage the BH3 domain of a neighboring effector protein to form a reciprocal, symmetric, BH3:groove dimer ([@bib8]). The assembly into high-molecular-weight complexes occurs through a second α6:α6 interface ([@bib9]). In addition, based on a structural similarity to α-pore-forming toxins (α-PFTs), execution of effector function may require membrane insertion of the central α5/α6 hairpin (pore domain) to form the mitochondria-permeabilizing pore ([@bib1; @bib13; @bib20; @bib23]).

To further delineate and characterize the steps required for the transition of native BAK into a membrane-permeabilizing pore, we combined biochemical and structural approaches to reveal a progressive sequence of (1) exposure of the BH3 domain, (2) N-terminal change, (3) oligomerization, and (4) insertion of the pore domain. By establishing a "BCL-X~L~ addiction" model system ([@bib4]), we found that BCL-X~L~ sequesters preactive, BH3-domain-exposed BAK. Release of this checkpoint by ABT-737 facilitates direct association with BIM promoting membrane insertion and subsequent cell death.

Results {#sec2}
=======

BAK Is Sequestered by BCL-X~L~ and Can Be Released by the BH3 Mimetic ABT-737 {#sec2.1}
-----------------------------------------------------------------------------

Although the activation of BAK may occur either directly or indirectly, a key feature of both models is the neutralization of antiapoptotic BCL-2 proteins by BH3-only proteins. To mimic this, we used ABT-737, which binds with high affinity to the hydrophobic groove of BCL-X~L~, BCL-2, and BCL-w and induces apoptosis in a BAK and/or BAX-dependent manner ([@bib25; @bib32; @bib33]). Jurkat cells exposed to ABT-737 exhibited classical apoptotic characteristics, including reduction in ΔΨ~m~, increased phosphatidylserine (PS) externalization, cytochrome *c* release, and processing of caspase-3 and poly (ADP-ribose) polymerase (PARP) ([Figures 1](#fig1){ref-type="fig"}A and 1B). As these cells lack BAX, ABT-737-induced apoptosis would be predicted to be solely dependent on BAK ([@bib31]). In agreement with this, suppression of BAK expression resulted in a marked decrease in PS externalization following ABT-737 treatment ([Figure 1](#fig1){ref-type="fig"}C).

According to the indirect activation model, BAK is held in check by antiapoptotic proteins ([@bib28; @bib37]). Immunoprecipitations revealed that BAK was associated with BCL-X~L~, but not BCL-2 or MCL-1 in Jurkat cells ([Figure 1](#fig1){ref-type="fig"}D; data not shown). ABT-737 antagonized BCL-X~L~ and efficiently displaced BAK compatible with features of the indirect model. Closer analysis of the supernatant fractions indicated that, although the target protein was completely depleted, a reciprocal reduction in its coprecipitated binding partner was not observed ([Figure 1](#fig1){ref-type="fig"}D, box). Thus, only a discrete portion of BAK appeared to be complexed with BCL-X~L~.

The direct activator BIM was also released from BCL-2 and BCL-X~L~ by ABT-737, and although its displacement was less efficient compared to BAK, released BIM could potentially act to "directly" activate inactive BAK ([Figures 1](#fig1){ref-type="fig"}E, 1F, and [S1](#figs1){ref-type="fig"}).

Reconstitution of BCL-X~L~:BAK Complexes Results in Sensitivity to ABT-737 {#sec2.2}
--------------------------------------------------------------------------

If the release of BAK from BCL-X~L~ is functionally important for ABT-737-induced apoptosis, then introduction of BCL-X~L~:BAK complexes into resistant cells should sensitize them to ABT-737. To exclude interference from endogenous Bak or Bax, BCL-X~L~:BAK complexes were introduced into Bax and Bak double-knockout (DKO) mouse embryonic fibroblasts (MEFs). As coexpressing BAK with BCL-X~L~ resulted in cell death, we first expressed BCL-X~L~ followed by tetracycline-induced expression of BAK ([Figure 2](#fig2){ref-type="fig"}A). Upon induction, BAK autoactivates but is then inhibited by a "sink" of BCL-X~L~ resulting in cells with BAK precomplexed to BCL-X~L~ exclusively. Reconstitution of BCL-X~L~:BAK complexes sensitized DKO MEFs to ABT-737 as assessed by PS externalization and processing of caspase-9 ([Figure 2](#fig2){ref-type="fig"}B). As in this model system, all induced BAK was sequestered, effectively "addicting" the cells to BCL-X~L~ ([Figure 2](#fig2){ref-type="fig"}C, box), and ABT-737-induced cell death was a result of BAK release from BCL-X~L~. Reconstitution of cells with MCL-1:BAK did not confer sensitivity to ABT-737 validating our model system ([Figures S2](#figs2){ref-type="fig"}A and S2B).

Introduction of BCL-X~L~:BIM or BCL-2:BIM complexes into human embryonic kidney 293T (HEK293T) cells did not alter sensitivity to ABT-737 ([Figures 2](#fig2){ref-type="fig"}D and 2E). Thus, BIM released from BCL-2 or BCL-X~L~ did not appear to exert a direct activator function on endogenous BAK or BAX, further suggesting that the reconstituted BCL-X~L~:BAK complexes are the preferential target of ABT-737. The model was then extended to characterize BCL-X~L~:BAK complexes. BAK associates with BCL-X~L~ through the canonical BH3:groove association ([@bib29]). In agreement, introduction of BAK BH3 mutants L78A or D83A into the reconstitution system revealed that, whereas both coimmunoprecipitated with BCL-X~L~, they were, in contrast to wild-type (WT) BAK, also recovered from the supernatant ([Figure 2](#fig2){ref-type="fig"}F). This implied both mutants displayed a reduced affinity for BCL-X~L~ and confirmed the requirement of the BH3 domain for complex formation. As this domain is occluded in inactive BAK, BCL-X~L~ sequesters a preactivated, BH3-domain-exposed conformation.

BAK N-Terminal Change Occurs Downstream of and Independent from BH3 Domain Exposure {#sec2.3}
-----------------------------------------------------------------------------------

In addition to BH3 domain exposure, conformational changes within the N-terminal region are also characteristic of BAK activation and are commonly determined by exposure of the Ab-1 epitope and increased trypsin sensitivity ([@bib13; @bib36]). Limited trypsin proteolysis on mitochondria isolated from ABT-737-treated Jurkat cells revealed a BAK cleavage fragment (p19), which was only detectable with the GLY82 antibody (epitope in the BH3 domain). In contrast, antibodies directed against the N-terminal region (NT and Ab-1) revealed a reduction in full-length BAK without detection of the p19 fragment, linking trypsin sensitivity to N-terminal change ([Figures 3](#fig3){ref-type="fig"}A, 3B, and [S3](#figs3){ref-type="fig"}). Together with formation of the p19 fragment, Ab-1-associated fluorescence was also detectable and occurred in the entire cell population, but not when cells were treated with an inactive enantiomer of ABT-737 ([Figure 3](#fig3){ref-type="fig"}C). Thus, N-terminal change required the neutralization of antiapoptotic proteins by ABT-737 and, by inference, this must occur downstream of BAK displacement from BCL-X~L~.

To further explore the relationship between displacement and N-terminal change, we established a double immunoprecipitation procedure: the first was directed against Ab-1-exposed BAK, followed by a second, on the resulting supernatant, against BCL-X~L~ ([Figure 3](#fig3){ref-type="fig"}D). When Jurkat cells were lysed in CHAPS (to retain BAK in its native conformation), Ab-1 failed to precipitate BAK and the BCL-X~L~:BAK complex was recovered from the resulting supernatant ([Figure 3](#fig3){ref-type="fig"}E, box). Thus, BAK complexed with BCL-X~L~ had not yet exposed the Ab-1 epitope. ABT-737 treatment resulted in the recovery of BAK by Ab-1, but BCL-X~L~ failed to coprecipitate suggesting that BAK exposes this epitope downstream of its release from BCL-X~L~ ([Figure 3](#fig3){ref-type="fig"}E). This was confirmed by the second immunoprecipitation, which recovered BCL-X~L~ without associated BAK. Taken together, these data demonstrated that the BAK N-terminal change occurred downstream of its displacement from BCL-X~L~.

As the BAK BH3 domain is required for association with BCL-X~L~, this further inferred that eversion of the BH3 domain occurred independent of and upstream of the N-terminal change. In addition, when the N terminus of BAK was artificially altered by Triton X-100, the BCL-X~L~:BAK complex was recovered in both immunoprecipitations ([Figure 3](#fig3){ref-type="fig"}E; [@bib8]). Thus, under these conditions, BCL-X~L~-sequestered BAK existed as a heterogeneous population of BH3-domain-exposed/Ab-1-exposed as well as BH3-domain-exposed/Ab-1-occluded conformations. Identical mixed conformations were also obtained by double immunoprecipitation with reconstituted cells solubilized in CHAPS and ABT-737 treatment, which resulted in conversion to an exclusively N-terminal changed population ([Figure 3](#fig3){ref-type="fig"}F). Thus, the N terminus can be altered either artificially with detergents or by "overexpression" without affecting the BH3:groove association highlighting the independence of both events.

BAK Oligomerizes following N-Terminal Change, a Pivotal, but Not Sufficient, Step toward MOMP {#sec2.4}
---------------------------------------------------------------------------------------------

The oligomerization of BAK into dimers and high-molecular-weight complexes is a prerequisite for MOMP and can be assessed using the redox catalyst copper(II)(1,10-phenanthroline)~3~ (CuPhe) ([@bib8; @bib10]). In untreated Jurkat cells, CuPhe induced the formation of an intramolecular disulfide bond between N-terminal C14 and α6-localized C166 resulting in a faster migrating band on SDS-PAGE (M~x~) ([Figure 4](#fig4){ref-type="fig"}A, left panel). ABT-737 treatment shifted the M~X~ form into disulfide-linked dimers (D) and higher molecular weight complexes (D^X^). Reduction of disulfide bonds resulted in the detection of solely monomeric BAK ([Figure 4](#fig4){ref-type="fig"}A, right panel).

Oligomerization involves two distinct interfaces, the BH3 domain/groove and the α6 helix ([@bib8; @bib9]). As the α6 helix is occluded by α1 helix in inactive BAK, the N-terminal change has to precede oligomerization. To analyze the chronology of the N-terminal change and oligomerization, BAK was restrained in its M~X~ conformation prior to activation. After incubation at 42°C to activate BAK ([@bib26]), oligomer formation as well as cytochrome *c* release was reduced compared to "unrestrained" BAK ([Figures 4](#fig4){ref-type="fig"}B and 4C). These results indicated that the N-terminal change must precede oligomerization possibly to enable exposure of the oligomerization interface, the α6 helix, to the protein surface.

Interference with the BH3:groove interface by utilizing a BAK L78A or an N-terminal-truncated BAK ΔN83, which lacks a major part of the BH3 domain, did not impair oligomer formation ([Figures 4](#fig4){ref-type="fig"}D and [S4](#figs4){ref-type="fig"}B). Despite undergoing oligomerization, L78A BAK failed to induce apoptosis as assessed by PS externalization and cytochrome *c* release ([Figures 4](#fig4){ref-type="fig"}E, 4F, and [S4](#figs4){ref-type="fig"}A). Oligomerization was not an artifact as L78A BAK also underwent N-terminal change, a prerequisite for oligomerization ([Figure 4](#fig4){ref-type="fig"}F). Therefore, the ability to oligomerize did not appear to determine the proapoptotic activity of BAK suggesting the requirement of additional steps to convert BAK into a membrane-permeabilizing pore.

BAK Inserts Its Pore Domain into the Outer Mitochondrial Membrane {#sec2.5}
-----------------------------------------------------------------

Membrane insertion of the BAX pore domain is associated with the formation of a MOMP-inducing pore ([@bib1; @bib2; @bib30]). We hypothesized that, following oligomerization, BAK inserts its pore domain into the membrane and the L78A mutant may be blocked at this stage accounting for its inactivity. The membrane topology of the α5/α6 hairpin in WT versus L78A BAK was analyzed by combining cysteine mutagenesis with 4-acetamido-4′-((iodoacetyl) amino) stilbene-2,2′-disulfonic acid (IASD) labeling ([@bib1; @bib15]). IASD only labels sulfydryl groups exposed to a hydrophilic environment resulting in the labeling of cysteine residues in the cytosol, the cytoplasmic boundary of a pore, or those facing the lumen of an aqueous pore. Cysteines embedded within the lipid bilayer or buried within a protein interface will be protected from IASD labeling ([Figure 5](#fig5){ref-type="fig"}A).

Cysteines were introduced in the pore domain of WT and L78A BAK using cysteine-deficient BAK (C14A/C166A) as a template. Insertions did not appreciably affect proapoptotic activity when overexpressed in DKO MEFs ([Figure S5](#figs5){ref-type="fig"}). As BAK is constitutively membrane-anchored, a cysteine insertion at residue L195 within the transmembrane region (α9 helix) served as a control. Following overexpression in DKO MEFs, both WT and L78A L195C exhibited an unaltered mobility on SDS-PAGE compared to the unlabeled control ([Figure 5](#fig5){ref-type="fig"}B). This protection from IASD labeling represented membrane insertion, as solubilization in CHAPS resulted in an IASD-mediated increase in molecular weight. In contrast, the N-terminal endogenous cysteine C14 in both WT and L78A was labeled by IASD indicating the constitutive cytosolic localization ([Figure 5](#fig5){ref-type="fig"}B).

If the killing conformations of BAK and BAX are analogous, then the α5/α6 hairpin should be embedded in the membrane and, as a result, cysteines within these helices would be expected to be protected from IASD labeling ([@bib1]). Conversely, if membrane insertion of the L78A mutant is impaired, then the corresponding cysteines would remain cytosolic and thus modified by IASD. In contrast a cysteine insertion at N124 (first N-terminal residue of the α5 helix) as well as the endogenous cysteine C166 (on the C-terminal end of the α6 helix) were modified by IASD in both WT and L78A BAK ([Figure 5](#fig5){ref-type="fig"}B). However, as both cysteines localize to the extremities of the α5 and α6 helices in WT BAK, they could represent the cytoplasmic boundary of a membrane-inserted pore domain ([Figure 5](#fig5){ref-type="fig"}A).

Cysteine residues with a more centralized localization within the α5/α6 helices should therefore be protected in the "killing conformation" of WT BAK. Despite this, residues R137C (α5 helix) as well as WT V154C and R156C (both α6 helix) were also labeled by IASD ([Figure 5](#fig5){ref-type="fig"}B). However, the labeling pattern of the corresponding L78A mutants differed by the presence of an IASD-protected species. Solubilization with CHAPS resulted in a complete shift to a labeled band, thus excluding the occlusion of these cysteines in a protein-protein interface and demonstrating there was sufficient IASD for labeling. These results indicated that the pore domain of L78A adopts a different membrane topology to WT BAK possibly explaining opposing apoptotic activities of WT and L78A BAK.

BIM Promotes Insertion of the BAK Pore Domain {#sec2.6}
---------------------------------------------

The different membrane topologies of WT compared to L78A BAK imply that adoption of the killing conformation was dependent on the BH3 domain. As the BH3 domain is part of the groove, the nonkilling, IASD-protected conformation of L78A could result from impaired engagement of a "ligand" BH3 domain which can be provided by a direct activator. In support of this hypothesis, we found that coexpression of the direct activator BIM with WT, but not L78A BAK, promoted cell death ([Figure 6](#fig6){ref-type="fig"}A). This synergism correlated with the coimmunoprecipitation of BIM with WT BAK, but not with the L78A mutant ([Figure 6](#fig6){ref-type="fig"}B). In this coexpression approach, WT BAK is already oligomerized when transfected alone indicating a role of BIM downstream of oligomerization possibly by promoting membrane insertion ([Figure 6](#fig6){ref-type="fig"}C).

In agreement, BIM altered the membrane topology of WT R137C or V154C by inducing a shift from the unlabeled to the IASD-labeled species ([Figure 6](#fig6){ref-type="fig"}D, box). Importantly, BIM did not alter the labeling pattern of the corresponding L78A mutants. However, both L78A and WT BAK gave a double band which was associated with cell death only with WT, but not L78A BAK. A similar pattern was also observed when WT BAK was overexpressed at an intermediate killing concentration ([Figure S6](#figs6){ref-type="fig"}A). Thus, the double band obtained with WT and L78A BAK may represent different membrane topologies.

To further investigate the effects of BIM on BAK, BIM expression was knocked down in the reconstitution system. Reduction of BIM expression resulted in a decrease of ABT-737-induced cell death ([Figure 6](#fig6){ref-type="fig"}E). We hypothesized that this effect should correlate with retention of WT R137C and V154C BAK in an IASD-protected nonkilling conformation ([Figures 6](#fig6){ref-type="fig"}D and [S6](#figs6){ref-type="fig"}A).

Agreeing with this, WT R137C was predominantly IASD-labeled and suppression of BIM resulted in reversion of the labeled to an unlabeled species which was independent of release from BCL-X~L~ by ABT-737 ([Figure 6](#fig6){ref-type="fig"}F). When reconstituted, BCL-X~L~ sequestered oligomeric BAK and thus this does not contradict the proposed order of oligomerization followed by membrane insertion ([Figures S1](#figs1){ref-type="fig"}, [4](#fig4){ref-type="fig"}A, and [S6](#figs6){ref-type="fig"}B). WT V154C gave a mixture of labeled and unlabeled species, and suppression of BIM reduced the IASD-labeled species, although this effect was only evident following ABT-737 treatment ([Figure 6](#fig6){ref-type="fig"}F, box). Taken together, these data revealed that the proapoptotic activity of WT BAK correlated with the conversion of an IASD-protected to a labeled conformation, which was promoted by interaction with BIM.

Discussion {#sec3}
==========

BAK and BAX are essential effectors of MOMP, the point of no return in apoptotic cell death, and as a consequence, their activation must be highly regulated. In this study, we demonstrate that activation of BAK involves several sequential but independent conformational changes, which provide different regulatory checkpoints mediated by members of the BCL-2 family. The antiapoptotic arm of this family functions to sequester a BH3-domain-exposed conformation of BAK preventing its further activation. BH3 mimetics, such as ABT-737, can release this checkpoint facilitating N-terminal change and oligomerization. The ability to oligomerize, however, did not correlate with cell death, and formation of a MOMP-inducing pore required association with the direct activator BIM.

The Initial Steps: BH3 Domain Exposure, N-Terminal Change, and Oligomerization {#sec3.1}
------------------------------------------------------------------------------

In agreement with the indirect activation model, we validated a role for BCL-X~L~ and MCL-1, but not BCL-2, in inhibiting BAK activation ([@bib28; @bib36; @bib37]; [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, and [S2](#figs2){ref-type="fig"}). BAK associates with BCL-X~L~ through the canonical BH3:groove interface, which is stabilized by hydrophobic and electrostatic interactions. Interference with either (L78A or D83A BAK BH3 mutants) reduced binding to BCL-X~L~ ([Figures 1](#fig1){ref-type="fig"}D, [2](#fig2){ref-type="fig"}C, and 2F; [@bib29]). By competing for the groove of BCL-X~L~, ABT-737 displaced BAK from BCL-X~L~ further establishing the importance of the BH3:groove association ([Figures 1](#fig1){ref-type="fig"}D and [2](#fig2){ref-type="fig"}C; [@bib25]). In inactive BAK, key stabilizing hydrophobic residues within the BH3 domain face the protein core and association with BCL-X~L~ requires rotation of the BH3 domain-containing α3 helix to evert these residues to the protein surface. This change involves the opening of the otherwise occluded hydrophobic groove (BH1--BH3 domains). Thus, BCL-X~L~ does not sequester inactive BAK but a preactivated, BH3-domain-exposed/open-groove conformation.

In contrast to BAK, in BAX the α9 helix (transmembrane anchor) occludes the groove/BH3 domain. Its disengagement is required to expose the BH3 domain/groove, which may be allosterically induced by association of activators with the BH3 trigger side to induce an N-terminal change ([@bib3; @bib11]). Thus, for BAX, N-terminal change precedes exposure of the BH3 domain/groove which is accompanied by translocation to the mitochondria. As BAK constitutively localizes to the mitochondria and the α1/α6 binding site is not as pronounced, it has been proposed that BAK can bypass this activation step resulting in constitutive exposure of the N terminus ([@bib14]). However, several lines of evidence suggest that the N terminus is initially occluded. Exposure of a cryptic antibody epitope (Ab-1), increased trypsin sensitivity, as well as the loss of the M~x~ form are associated with the N-terminal change and exclusively occurred following ABT-737 treatment ([@bib13; @bib36]; [Figures 3](#fig3){ref-type="fig"}B, 3C, and [4](#fig4){ref-type="fig"}D). By mapping the Ab-1 epitope to Y38 to the middle of the α1 helix, we attribute the increased accessibility to this epitope to a major reorganization of the N-terminal region (α1 and α2 helices) rather than the simple exposure ([Figure S3](#figs3){ref-type="fig"}). However, despite the close proximity of the N-terminal region with the BH3 domain, the N-terminal change occurred independent and downstream of BH3 domain exposure as BCL-X~L~-sequestered BAK existed exclusively in an N-terminal-occluded conformation ([Figures 3](#fig3){ref-type="fig"}E and 3F). Furthermore, the N-terminal change is a prerequisite for oligomerization, as the formation of oligomers could be blocked by inhibiting the N-terminal change ([Figures 3](#fig3){ref-type="fig"}C, [4](#fig4){ref-type="fig"}A, and 4B). This supports the proposed model for oligomerization as the N terminus occludes the α6 helix which represents the interface for BH3:groove-linked dimers to associate into oligomers ([@bib8; @bib9]). However, the apparent, indispensable role of the BH3 domain in oligomer formation is unclear as both BAKΔN83 as well as BAK L78A both form oligomers ([Figures 4](#fig4){ref-type="fig"}D and [S4](#figs4){ref-type="fig"}B). Although BAK is oligomeric in the reconstitution system, BH3 domains appear to be available both to facilitate a BH3:groove association with BCL-X~L~ and to allow interaction with BIM ([Figures 6](#fig6){ref-type="fig"}B and [S6](#figs6){ref-type="fig"}B). Despite this, the BH3 domain clearly contributes to BAK proapoptotic function, as both BAKΔN83 as well as L78A lost their killing ability ([Figures 4](#fig4){ref-type="fig"}E and [S4](#figs4){ref-type="fig"}A). Thus, in analogy to BAX, a BH3-domain-dependent step must occur downstream of oligomerization ([@bib16]).

The BAK BH3 Mutant, L78A, Is Blocked at a Prepore Conformation {#sec3.2}
--------------------------------------------------------------

Structural similarities between α-PFTs prompted the hypothesis that BAK and BAX insert into the membrane to mediate MOMP ([@bib23]). The membrane-inserting domains of α-PFTs are composed of a hydrophobic, central, helical hairpin which, in the native conformation, is surrounded by amphipathic helices. During activation, a series of conformational changes opens up these outer layers to expose the central hairpin, which then spontaneously penetrates the membrane ([@bib27]). By analogy, during BAK activation, the outer α1 helix repositions away from the protein core exposing the α6 helix, which together with the α5 helix resembles the central hairpin of the PFTs. However, the pore domain of BAK is comprised of largely amphipathic helices, which are not expected to spontaneously membrane insert. The occlusion of polar surfaces within tertiary contact sides may energetically favor membrane insertion ([@bib34; @bib35]). By analogy, BAK assembled into high-molecular-weight complexes prior to membrane insertion (membrane anchored conformation; [Figure S7](#figs7){ref-type="fig"}i) and consequently could be labeled by IASD ([Figures 5](#fig5){ref-type="fig"}B and [6](#fig6){ref-type="fig"}D; labeled band with L78A R137C and V154C). This effectively concentrated these subunits on the membrane surface potentially facilitating the coordinated membrane insertion ([Figure S7](#figs7){ref-type="fig"}ii). Evidence for a membrane-inserted conformation was suggested by the protection of R137C and V154C from IASD when using sublethal concentrations of WT BAK ([Figure 6](#fig6){ref-type="fig"}D) or in L78A BAK ([Figures 5](#fig5){ref-type="fig"}B and [6](#fig6){ref-type="fig"}D). However, this labeling pattern was not associated with killing and consequently could not represent the final pore but rather a prepore conformation ([Figures S6](#figs6){ref-type="fig"} and [S7](#figs7){ref-type="fig"}ii). In contrast, when WT BAK R137C and V154C were expressed at killing concentrations, they were accessible to IASD ([Figure 5](#fig5){ref-type="fig"}B). Considering that in active BAK the α5 and α6 helices have to adopt a transmembrane/membrane-inserted conformation ([@bib24]), accessibility to IASD could be explained by the localization of these residues to the lumen of an aqueous pore. In support of this, amphipathic helices, like the pore domain of BAK, were shown to orientate their polar patches toward the lumen of the pore to expose nonpolar surface to the hydrophobic core of the bilayer ([@bib12; @bib17]). BAX is also described to form an ion-conductive, aqueous pore implying that polar residues within the pore domain must orientate to the lumen of the pore ([@bib2; @bib30]). Thus, several lines of evidence point toward a membrane-inserted pore domain lining the lumen of an aqueous MOMP pore. This provides a possible explanation for the observed shift from unlabeled to labeled conformations which correlated with cell death. The pore domain seemed to reorientate within the membrane from a state where the pore domain was "partially" inserted into the membrane (IASD-protected) to the mature MOMP-inducing pore (IASD-labeled). As pore formation appeared to be a highly dynamic process ([Figure S6](#figs6){ref-type="fig"}A), a continuous flux from membrane-anchored to pore conformation could occur, possibly explaining the detection of double bands under certain conditions.

BIM Promotes the Conversion of Prepore BAK to the Pore Conformation {#sec3.3}
-------------------------------------------------------------------

Multidomain BCL-2 family members, such as BAK, are capable of acting both as ligand or receptor. Inserting its BH3 domain into the hydrophobic binding groove of antiapoptotic BCL-2 proteins affords BAK ligand characteristics, whereas the structurally juxtaposed BH1--BH3 domains form a hydrophobic groove, which can act as a receptor for the BH3 domain of direct activator proteins ([@bib7; @bib14; @bib19]). Activator engagement promotes the exposure of the effector BH3 domain and opening of the groove, thereby creating the interfaces required for oligomerization.

In our model, we could not find any direct activator role of BIM on endogenous BAK or BAX following its release from BCL-X~L~ ([Figure 2](#fig2){ref-type="fig"}D). However, the importance of direct activators in the initial activation of both BAK and BAX has been demonstrated recently using "BH3-stabilized α helices of BCL-2 proteins" or BH3 peptides on recombinant full-length or truncated effectors ([@bib7; @bib19; @bib22]).

In agreement, BIM synergized with BAK proapoptotic function as coexpression of both proteins enhanced and vice versa and decrease of BIM levels reduced cell death ([Figures 6](#fig6){ref-type="fig"}A and 6E). This effect was only evident with WT, but not L78A BAK, implying the requirement of an intact receptor surface to accommodate the BH3 domain of the activators. The direct activator role of BIM is attributed to the induction of BAK oligomerization ([@bib5; @bib14]). However, in both model systems used, coexpression or reconstitution, BAK was oligomerized prior to BIM association ([Figures 6](#fig6){ref-type="fig"}C and [S6](#figs6){ref-type="fig"}B). Although we cannot exclude a possible involvement of BIM in the initial activation of BAK, our results suggest BIM can also act downstream of oligomerization in an unappreciated role to convert the membrane topology of oligomerized, partially membrane-inserted prepore BAK to the killing pore conformation. This hypothesis is supported by our finding that coexpression of BIM shifted WT R137C and V154C from an IASD-protected to a labeled species, whereas knockdown of BIM reversed this ([Figures 6](#fig6){ref-type="fig"}D and 6F). The N-terminal part of the α5 helix (amino acids 124--136) comprises the BH1 domain and thus participates in groove formation. Complete membrane insertion of this helix would effectively destroy the hydrophobic groove causing a loss of receptor characteristic. This would suggest that in prepore BAK, protection from IASD-labeling may represent the partial insertion of the α5 helix to maintain the structure and function of the groove and thus facilitate engagement with the BIM BH3 domain ([Figures 6](#fig6){ref-type="fig"}D and 6F). BIM could then promote conformational changes within the groove leading to complete insertion of the pore domain.

In summary, our results reveal that BAK activation is a complex process that includes a series of independent steps ([Figure 7](#fig7){ref-type="fig"}). Although BAK adopts an oligomeric conformation after its release from BCL-X~L~, this conformation does not induce MOMP. We have identified a requirement for the direct activator BIM to convert oligomerized prepore BAK into a membrane-permeabilizing pore. Therefore, BAK activation does not exclusively occur through the direct or indirect activation models but rather combines aspects of both. These additional steps provide further unappreciated checkpoints to control activation and prevent unwanted/accidental cell death and also open up possible opportunities for tumors to deregulate apoptosis.

Experimental Procedures {#sec4}
=======================

Detailed description of cell culture, immunoprecipitation, limited proteolysis, Ab-1 staining, transfection methods, and cell death analysis are provided in the [Extended Experimental Procedures](#dtbox1){ref-type="boxed-text"}.

Constructs {#sec4.1}
----------

pcDNA3.1, pcDNA4TO, pcDNA6, and pcDNA6-TetR were obtained from Invitrogen. Human BAK was cloned into pcDNA4TO with an N-terminal Strep-Tag II. Strep-Flag double-tagged BCL-X~L~ and BIM~EL~ were cloned into pcDNA6. Constructs were transiently transfected into Bax and Bak DKO MEFs (obtained from Drs. A. Strasser and D. Huang, The Walter and Eliza Hall Institute of Medical Research) using JetPrime (Polyplus) or HEK293T cells using Jet PEI (Polyplus) according to manufacturer's protocol. Where indicated, site-directed mutagenesis was performed using Quikchange Multi (Agilent Technologies), and all constructs were sequence-verified prior to use.

Reconstitution of BCL-X~L~:BAK Complexes {#sec4.2}
----------------------------------------

Cells were transiently transfected with BAK, TetR, and BCL-X~L~ constructs at ratios 1:10 (BAK:TetR) and 1:1 (BAK:BCL-X~L~). BAK was induced with tetracycline (4 μg/ml; Calbiochem) at 24 hr posttransfection for 4 hr prior to treatment with ABT-737.

Analysis of BAK Oligomers Using CuPhe {#sec4.3}
-------------------------------------

Formation of BAK high-molecular-weight complexes was analyzed using the redox catalyst CuPhe. Mitochondria-enriched fractions from Jurkat cells or digitonin-generated heavy membrane fractions from MEFs were solubilized in X-link Buffer (100 mM sucrose, 20 mM HEPES-KOH \[pH 7.4\], 2.5 mM MgCl~2~, and 50 mM KCl) and incubated with CuPhe (20 mM 1,10 phenanthroline with 300 mM CuSO~4~) for 30 min on ice. The reaction was then quenched by incubation with 100 mM EDTA for 15 min and mitochondria-enriched fractions recovered. Oligomerization of BAK was analyzed by SDS-PAGE under nonreducing conditions.

Assessment of BAK Membrane Topology Using IASD Labeling {#sec4.4}
-------------------------------------------------------

BAK cysteine insertion mutants were transiently transfected into DKO MEFs or HEK293T cells. Heavy membrane fractions were obtained by mild digitonin lysis and washed with 10 mM dithiothreitol (DTT) to ensure reduction of sulfydryl groups. Pellets were resuspended in X-link buffer and incubated with 10 μM IASD for 30 min at room temperature. Reactions were quenched by addition of 100 mM DTT and mitochondria-containing fractions recovered. Resulting pellets were solubilized in 2% CHAPS and IASD modification analyzed by SDS-PAGE followed by western blotting on large-format SDS-PAGE gels. As controls, samples were left unlabeled or lysed in 2% CHAPS prior to IASD labeling.

Extended Experimental ProceduresCell CultureCell lines were obtained from the European Collection of Animal Cell Cultures (ECACC; Porton Down, UK) except where indicated. Jurkat cells (clone E6.1) were maintained in Roswell Park Memorial Institute (RPMI) medium containing 10% fetal calf serum (FCS) and 5% Glutamax™ (Life Technologies Inc. Paisley UK), Human Embryonic Kidney Fibroblasts (HEK293T) and MEFs deficient in BAX and BAK were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (FCS) and 5% Glutamax™.Cell Death Induction and Apoptosis QuantificationThe intrinsic apoptotic pathway was induced by treatment with ABT-737 (Abbott laboratories, Illinois, USA) with the concentration used dependent on the cell type (3-30 μM). Apoptosis was measured using Annexin V and propidium iodide (PI) staining. For non-adherent cells, Annexin buffer (10 mM HEPES/NaOH (pH 7.4), 150 mM NaCl, 5 mM KCl, 1 mM MgCl~2~, 1.8 mM CaCl~2~) supplemented with Annexin V-FITC was added to the cells. After incubation for 10 min, propidium iodide was added and cells analyzed on a FacScan flow cytometer using CELLQuest software (Becton Dickinson, Oxford UK). For adherent lines, both detached and trypsinized cells were resuspended in fresh medium and left to recover prior to staining. Staining procedure was then identical to the suspension cells. TMRE was used to measure the loss in mitochondrial membrane potential (ΔΨ~m~). TMRE (100 nM) was added to medium and cells incubated at 37°C for 10 min in the dark prior to analysis by flow cytometry. Both TMRE and Annexin V measurements were made on the whole cell population.Analysis of BAK N-Terminal Conformation -- Ab-1 Staining and Flow CytometryFor intracellular Ab-1 staining, cells were fixed with 2% paraformaldehyde at room temperature for 10 min, washed with PBS and resuspended in permeabilization buffer (0.1% saponin and 0.5% BSA in PBS) containing BAK Ab-1 antibody (Calbiochem, Nottingham, UK) (1:100 dilution). After incubation for 1 hr at 4°C, cells were washed and incubated with goat anti-mouse IgG-Alexa Fluor® 488 (Invitrogen) diluted 1:100 into permeabilization buffer. After washing in PBS, cells were analyzed by flow cytometry.Limited Trypsin ProteolysisFor limited trypsin proteolysis, mitochondria enriched fractions were resuspended in X-Link buffer (100 mM sucrose, 20 mM HEPES-KOH pH 7.4, 2.5 mM MgCl~2~, 50 mM KCl) and 125 μg trypsin/50 μg protein was added. Following incubation for 20 min on ice trypsin was inhibited by addition of 4 mM Pefabloc SC (Roche Diagnostics, Basel, Switzerland). Mitochondria enriched fractions were recovered and analyzed by SDS-PAGE.Ab-1 Staining and Confocal MicroscopyFor immunofluorescent staining, cells were grown on coverslips and transfected as described. After 24 hr, cells were fixed with 4% (v/v) paraformaldehyde and permeabilized with 0.5% saponin in PBS. Cells were then incubated with anti-cytochrome *c* and Ab-1 followed by the appropriate fluorophore-conjugated secondary antibodies (Alexa 547 for cytochrome *c* and Alexa 488 for Ab-1) and Hoechst 33342. Coverslips were then mounted on glass slides and subjected to confocal microscopy on a Zeiss LSM510.Subcellular FractionationHeavy membrane (HM) fractions were generated by resuspending in mitochondrial isolation buffer (250 mM sucrose, 20 mM HEPES, pH 7.4, 5 mM MgCl~2~ and 10 mM KCl) containing 0.01% digitonin. Cells were left on ice followed by centrifugation at 13000 rpm for 3 min. Supernatant (cytosolic fraction) and pellets (HM fraction) were analyzed by Western blotting or further processed. For preparation of mitochondria enriched fractions, Jurkat cells were resuspended in buffer (10 mM NaCl, 1.5 mM MgCl~2~, 10 mM Tris-HCl) and left for 10 min on ice. Hypotonic swelling was stopped by addition of buffer (525 mM mannitol, 175 mM sucrose, 12.5 mM Tris-HCl pH 7.5, 2.5 mM EDTA) and cells ruptured by Dounce homogenization. After clearing lysates at 2700 rpm for 10 min, mitochondria enriched fractions were pelleted at 13 000 rpm for 15 min and washed in X-link buffer.siRNA TransfectionsJurkat cells were transfected using Nucleofection (Amaxa, Köln, Germany), following the manufacturer's instructions with a single BAK siRNA GCUUUAGCAAGUGUGCACUtt, Ambion, Paisley UK) or a pool of siRNAs (CGACAUCAACCGACGCUAUtt, UAUGAGUACUUCACCAAGAtt, GACGGCAGCUCGCCAUCAUtt, AAUCAUGACUCCCAAGGGUtt, Thermo Fischer), at a final concentration of 75 nM. A nonspecific control pool, containing four pooled nonspecific siRNA duplexes, was used as a negative control. For BIM knockdown three single siRNAs (BIM-1, GACCGAGAAGGUAGACAAUtt; BIM-2, GCAACCUUCUGAUGUAAGUtt; BIM-3, CCUCCCUACAGACAGAGCCtt \[Ambion\]) were transfected independently into HEK293T cells using Interferin (PolyPlus) according to the manufacturer's protocol. After 24 hr, cells were reconstituted with BCL-X~L~:BAK complexes. After a further 48 hr (BAK) or 72 hr (BIM), knockdown efficiency was determined by SDS-PAGE and the cells further processed.ImmunoprecipitationsFor immunoprecipitation, cells were lysed in Lysis Buffer (20 mM Tris-HCl pH 7.4, 135 mM NaCl, 1.5 mM MgCl~2~, 1 mM EGTA, 10% glycerol) containing 1% CHAPS or 1% Triton X-100 and supplemented with protease inhibitor cocktail (Roche Diagnostics, Switzerland) and incubated on ice for 20 min. Lysates were pre-cleared by centrifugation at 13000 rpm for 15 min. Rabbit BAK Ab (Upstate Biotechnology), mouse BAK Ab-1 antibody (Calbiochem), rabbit BCL-X~L~ antibody (BD Biosciences), hamster BCL-2 antibody (BD Bioscience), rabbit BIM antibody (Cell signaling Technologies) or rabbit MCL-1 antibody (Epitomics, Burlingame CA) were crosslinked to Protein A-Dynabeads using 20 mM dimethylpimelimidate (Fluka Biochemika, Switzerland). Crosslinked antibodies were incubated with 0.5-1 mg protein for 12 hr at 4°C. Beads were washed with lysis buffer supplemented with Tween-20 before elution in sodium dodecyl sulfate (SDS) loading buffer and western blotting. Immunoprecipitations against Strep-Tag II or Flag-tag were carried out using streptavidin coated agarose beads (IBA, Goettingen Germany) or anti-Flag M2 crosslinked agarose beads (Sigma Aldrich, Dorset UK).Crosslinking of BAK Oligomers Using EGSMitochondria enriched fractions from Jurkat cells or digitonin generated heavy membrane fractions from MEFs were solubilized in X-link buffer and incubated with CuPhe (20 mM 1,10 phenanthroline with 300 mM CuSO~4~) for 30 min on ice. Heavy membrane fractions were incubated with EGS (5 μM) for 30 min on ice. Membranes were then centrifuged and pellets resuspended in 1x SDS loading buffer. BAK complexes were then analyzed by SDS-PAGE.StatisticsAll statistics were performed using SPSS, and significant differences were determined using a one-way ANOVA with a Fisher's Least Significant Difference post hoc analysis.

Supplemental Information {#app2}
========================

Document S1. Article plus Supplemental Information

We thank Dr. S. Rosenberg (Abbott Laboratories) for providing us with ABT-737, Dr. A. Strasser for the Bax and Bak DKO MEFs, Dr. S. Bratton (MD Anderson, Austin, Texas) for help with the statistical analysis, Prof. M. MacFarlane (MRC Toxicology Unit) for support of the work when under revision, and Dr. S. Varadarajan (MRC Toxicology Unit) for his help with immunofluorescent staining. This work was supported by the Medical Research Council and grants from the Marie Curie Research Training Network "ApopTrain" (to K.W. and G.M.C.).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

Supplemental Information includes Extended Experimental Procedures and seven figures and can be found with this article online at [http://dx.doi.org/10.1016/j.celrep.2013.09.010](10.1016/j.celrep.2013.09.010){#intref0010}.

![BAK and BIM Are Displaced from BCL-X~L~ by ABT-737\
(A and B) ABT-737 triggers the intrinsic apoptosis pathway. (A) Jurkat cells were treated with ABT-737 (5 μM) and the percentage of apoptotic cells determined at the indicated times by using tetramethylrhodamine ethyl ester to measure mitochondrial membrane potential (ΔΨ~m~) and Annexin V staining for the externalization of phosphatidylserine (PS). Data represent the mean ± SEM from eight different experiments. (B) Processing of caspase-3 and cleavage of PARP were analyzed following ABT-737 treatment. Cytochrome *c* release was assessed by digitonin fractionation. HM, heavy membrane fraction.\
(C) ABT-737-induced cell death is BAK-dependent. Jurkat cells were transiently transfected with a single BAK siRNA (BAK), a pool of BAK siRNAs (pool), a control siRNA (con), or left untransfected (ut). After 48 hr, cells were treated with ABT-737 (5 μM) and PS externalization assessed at indicated times. ^∗^p \< 0.05 compared to untreated cells. Levels of BAK were analyzed by western blotting.\
(D) ABT-737 displaces BAK from BCL-X~L~. Jurkat cells were treated with ABT-737 (5 μM), lysed in 1% CHAPS, and subjected to immunoprecipitation using either BAK or BCL-X~L~ antibodies. IP, immunoprecipitation. The asterisk denotes a nonspecific band.\
(E and F) ABT-737 displaces BIM from BCL-X~L~ and BCL-2. Cells treated with ABT-737 (5 μM) were subjected to immunoprecipitation for either (E) BIM and BCL-X~L~ or (F) BIM and BCL-2. The asterisk denotes nonspecific bands.\
See also [Figure S1](#figs1){ref-type="fig"}.](gr1){#fig1}

![Reconstitution of BCL-X~L~:BAK Complexes Sensitizes Cells to ABT-737\
(A and B) Schematic representation of the BCL-X~L~ addiction model system as illustrated by the example of BCL-X~L~:BAK. Bax and Bak DKO MEFs were transiently transfected with BCL-X~L~ (constitutive expression), BAK (under the control of tetracycline \[TET\]-inducible promoter) and a plasmid encoding the TET-repressor protein (TETR) to reconstitute BCL-X~L~:BAK complexes (rec) or with empty vector (con). After 24 hr of BCL-X~L~ expression, BAK was induced for 4 hr with tetracycline and became complexed with by BCL-X~L~. ABT-737 neutralizes BCL-X~L~ resulting in the displacement of BAK. (B) Reconstitution of BCL-X~L~:BAK complexes sensitizes cells to ABT-737. DKO MEFs reconstituted with BCL-X~L~:BAK complexes or MOCK-transfected (con) were treated with ABT-737 (3 and 30 μM) for 4 hr and cell death assessed by PS externalization (data points represent the mean ± SEM from three different experiments) and caspase-9 processing (asterisks denote nonspecific bands). ^∗^p \< 0.05 compared to control; \#p \< 0.001 compared to untreated reconstituted cells.\
(C) Induced BAK associates with BCL-X~L~ and is displaced by ABT-737. BCL-X~L~:BAK-reconstituted or MOCK-transfected (con) DKO MEFs were treated with ABT-737 (3 μM) for 4 hr, lysed in 1% CHAPS, and subjected to immunoprecipitation using a BCL-X~L~ antibody.\
(D and E) ABT-737-released BIM does not induce apoptosis in reconstituted cells. BAK was replaced with BIM, and HEK293T cells were reconstituted with BCL-X~L~:BIM, BCL-2:BIM, or as a control BCL-X~L~:BAK complexes. BIM-reconstituted cells were exposed to ABT-737 (5 or 10 μM) for 3 hr and (D) externalization of PS was determined (data points represent the mean ± SEM from three different experiments) or (E) BCL-2 or BCL-X~L~ was precipitated from CHAPS lysates using StrepTactin Sepharose.\
(F) The BAK BH3 domain is involved in association with BCL-X~L~. BAK BH3 mutants L78A and D83A were introduced into the reconstitution system in HEK293T cells or MOCK-transfected (con). Cells were lysed in 1% CHAPS and lysates subjected to immunoprecipitation using a BCL-X~L~ antibody.\
See also [Figure S2](#figs2){ref-type="fig"}.](gr2){#fig2}

![N-Terminal Change Occurs Downstream of the Release of BAK from BCL-X~L~\
(A) Schematic representation of BAK and location of Ab-1, NT, and GLY82 antibody epitopes are indicated. The trypsin cleavage site is marked by an arrow, and the resulting p19 fragment is shown.\
(B) The BAK N terminus became trypsin-sensitive following ABT-737 treatment. Mitochondria from ABT-737-treated Jurkat cells (5 μM for indicated times) were isolated by Dounce homogenization and subjected to limited trypsin proteolysis. Cleavage of BAK was analyzed using a panel of BAK antibodies (Gly82, NT, and Ab-1). PefablocSC (inhibitor) was included as a control.\
(C) The Ab-1 epitope is exposed following ABT-737 treatment. Jurkat cells were treated with ABT-737 (5 μM) or its inactive enantiomer (5 μM) for the indicated times. Cells were then labeled with BAK Ab-1/ALEXA488-labeled antibodies (open histogram) or secondary antibody alone (con, filled histogram) and analyzed for Ab-1-associated fluorescence by flow cytometry.\
(D) Double immunoprecipitation procedure to determine N-terminal conformation of BCL-X~L~-sequestered BAK. A first immunoprecipitation is directed against N-terminally changed BAK using the Ab-1 antibody. The resulting supernatant fraction is then subjected to a second immunoprecipitation against BCL-X~L~.\
(E) Ab-1 exposure occurs downstream of BAK displacement from BCL-X~L~. ABT-737-treated Jurkat cells (5 μM for the indicated times) were lysed in 1% CHAPS or 1% Triton X-100 and lysates subjected to double immunoprecipitation.\
(F) Reconstituted BAK is present as mixed population of N-terminal exposed and occluded forms. BCL-X~L~:BAK-reconstituted or MOCK-transfected (con) DKO MEFs were treated with ABT-737 (30 μM) for 4 hr and lysed in 1% CHAPS. Lysates were subjected to double immunoprecipitation (as detailed in D).\
See also [Figure S3](#figs3){ref-type="fig"}.](gr3){#fig3}

![Oligomerization Does Not Represent the Final Step for Commitment to Apoptosis\
(A) BAK oligomerizes during apoptosis. Jurkat cells were treated with ABT-737 (5 μM) for the indicated times. Mitochondria were then isolated and disulfide bonds introduced using CuPhe. Formation of BAK dimers and oligomers was analyzed by western blotting under nonreducing conditions (left panel) and specificity of bands confirmed using reducing conditions (right panel). M~x~, intramolecular-disulfide bond, inactive BAK; M, monomeric BAK; D, intermolecular-disulfide bond, dimeric BAK; D^x^, high-molecular-weight complexes; i, interface between stacking and running gel; b, bottom of the sample well.\
(B and C) Restraining BAK in the M~X~ conformation impairs its proapoptotic function. Enriched mitochondrial fractions from control Jurkat cells were exposed to two different concentrations of CuPhe. "M~X~-trapped" BAK was then heat-activated (42°C for 30 min) followed by analysis of (B) disulfide-linked oligomer formation and (C) cytochrome *c* release.\
(D) BAK L78A still oligomerizes. WT and L78A BAK were transiently transfected into DKO MEFs. Oligomer formation was assessed 24 hr posttransfection using CuPhe and western blotting under nonreducing conditions.\
(E) The BAK BH3 mutant, L78A, fails to induce apoptosis in Bax and Bak DKO MEFs. The asterisk denotes p \< 0.05, and L78A was significantly different from wild-type.\
(F) L78A BAK undergoes N-terminal change but fails to release cytochrome *c*. DKO MEFs were transfected with WT or L78A BAK for 24 hr; fixed, permeabilized, and stained with Ab-1 (green), Hoechst 33342, and anti-cytochrome *c* (red); and examined by confocal microscopy. L78A BAK-staining colocalized with mitochondria but did not release cytochrome *c* in contrast to WT BAK.\
See also [Figure S4](#figs4){ref-type="fig"}.](gr4){#fig4}

![L78A BAK Adopts a Different Membrane Topology Compared to Wild-Type BAK\
(A) Schematic representation of IASD accessibility/protection of cysteine residues in the context of a membrane environment. Cysteine residues, which are orientated to a hydrophilic environment, such as cytosol, lumen of an aqueous pore, or pore boundary, are accessible to IASD. In contrast, cysteines which are buried within hydrophobic protein interfaces or inserted into the hydrophobic membrane core are protected from IASD labeling. Both possibilities can be discriminated by solubilization in CHAPS.\
(B) IASD-labeling pattern of L78A differs from WT BAK. Cysteines along the α5/α6 hairpin (pore domain) were introduced into cysteine-deficient WT or L78A BAK. Labeling controls were provided by L195C (within the α9 helix; transmembrane domain; constitutively membrane inserted) and the endogenous cysteine C14/C166A (N terminus; constitutively extramembranous). L78A and WT cysteine insertions were expressed in DKO MEFs at killing concentrations (1000 ng), HM fractions generated and labeled with IASD. Western blotting was used to detect labeled (L) and unlabeled (UL) species. A CHAPS-solubilized sample was included as a positive labeling control.\
See also [Figure S5](#figs5){ref-type="fig"}.](gr5){#fig5}

![BIM Alters Membrane Topology of the α5/α6 Hairpin of WT but Not L78A BAK\
(A) Coexpression of WT, but not L78A BAK, with BIM promotes proapoptotic activity. WT or L78A BAK was coexpressed with BIM in Bax and Bak DKO MEFs, and cell death was analyzed after 16 hr by PS externalization. The asterisk denotes p \< 0.05 compared to Bim alone. NS, not significantly different compared to BIM alone.\
(B) BIM coprecipitates with WT but not L78A. WT or L78A BAK were cotransfected with BIM in DKO MEFs. Cells were lysed in 1% CHAPS and BAK-precipitated using StrepTactin Sepharose. Interaction with BIM was analyzed by western blotting.\
(C) BIM does not affect oligomerization of BAK. WT or L78A BAK was coexpressed with BIM and oligomerization assessed with CuPhe.\
(D) BIM converts WT BAK from an IASD-unlabeled (UL) protected to labeled (L) conformation. WT or L78A R137C and V154C BAK were coexpressed at a sublethal concentration (500 ng) with BIM in DKO MEFs and HM fractions labeled with IASD.\
(E) BIM siRNA results in reduced ABT-737 sensitivity in the reconstitution system. HEK293T cells were transfected with three different BIM siRNAs or con siRNA (MOCK). After 24 hr, cells were reconstituted with BCL-X~L~:BAK complexes and treated with ABT-737 (5 μM for 3 hr). Cell death was determined by PS externalization. ^∗^p \< 0.05 compared to MOCK-transfected cells.\
(F) BIM siRNA reverts WT BAK to an IASD-protected (UL) conformation. Following transfection with two different BIM siRNAs, BCL-X~L~:BAK R137C or BAK V154C complexes were reconstituted and treated with ABT-737 (5 μM for 3 hr). HM fractions were generated and subjected to IASD labeling.\
See also [Figure S6](#figs6){ref-type="fig"}.](gr6){#fig6}

![Schematic Model of BAK Activation\
Inactive BAK is monomeric and adopts a closely packed, globular conformation with both the BH3 domain and groove occluded. Eversion of key hydrophobic residues within the BH3 domain to the protein surface results in groove opening and facilitates association with BCL-X~L~ through a BH3:groove interface. This interaction with BCL-X~L~ serves as a checkpoint to block further activation of BAK, thereby maintaining cell survival. Neutralization of BCL-X~L~ by ABT-737 results in the release of BAK, which then undergoes an N-terminal change followed by oligomerization. Activation of BAK up to this point is compatible with activation by the indirect model. Oligomerized BAK assumes a prepore conformation with the α5/α6 helices partially inserted in the mitochondrial membrane. Association with BIM results in the conversion of prepore WT BAK into a fully membrane-inserted, membrane-permeabilizing pore with the subsequent release of cytochrome *c* and the induction of apoptosis. BIM fails to interact with oligomerized and partially membrane-inserted BAK L78A, which remains in its inactive "prepore" conformation. Thus, the activation of BAK reflects an interplay between direct and indirect activation models.\
See also [Figure S7](#figs7){ref-type="fig"}.](gr7){#fig7}

![BIM Is Not as Efficiently Displaced as BAK from BCL-X~L~, Related to [Figure 1](#fig1){ref-type="fig"}\
Jurkat cells were exposed to ABT-737 (5 μM) for the indicated times, lysed in 1% CHAPS and subjected to immunoprecipitation using a BCL-X~L~ antibody. Immunoprecipitates were analyzed for binding partners by Western blotting. Asterisks represent non-specific bands.](figs1){#figs1}

![BCL-2 Does Not Inhibit BAK-Induced Apoptosis or Sequester BAK, Related to [Figure 2](#fig2){ref-type="fig"}\
HEK293T cells were reconstituted with BCL-X~L~:BAK, BCL-2:BAK or MCL-1:BAK complexes. Reconstituted cells were exposed to ABT-737 (5 μM, 3 h) and (A) apoptosis assessed by PS externalization or (B) To assess MCL-1 and BCL-2 complex formation, BAK was isolated from CHAPS lysates of reconstituted cells using Strep-Tag II coated beads. As BCL-XL also had a Strep-Tag, BAK was immunoprecipitated using an anti-BAK antibody. Interaction with anti-apoptotic proteins was then determined by western blotting. Asterisks denote non-specific bands.](figs2){#figs2}

![The Ab-1 Epitope in BAK Maps around Residue Y38, Related to [Figure 3](#fig3){ref-type="fig"}\
(A) N-terminal BAK truncations (ΔN23 and ΔN42) and mutants (T31R, F35A and Y38R) were transiently transfected into Bax and Bak DKO MEFS (DKO MEFS) and cells were analyzed by western blotting using the indicated antibodies.\
(B) BCL-X~L~:BAK wt and mutant complexes were reconstituted in HEK293T cells and BAK N-terminal status analyzed by intracellular staining Ab-1 staining. ut - untransfected.](figs3){#figs3}

![The BH3 Domain of BAK Is Required for BAK Proapoptotic Function, but Not Oligomerization, Related to [Figure 4](#fig4){ref-type="fig"}\
N-terminal BAK truncations were generated (NΔ23, NΔ42, NΔ69, NΔ83) and transiently transfected into DKO MEFs. (A) After 24 hr PS externalization was analyzed post transfection and protein levels determined by western blotting. ^∗^p \< 0.05, from untreated, \#p \< 0.05, from wild-type. (B) Formation of oligomers was assessed by crosslinking of HM fractions with ethylene glycol bis(sulfosuccinimidyl succinate) (EGS). D^X^ represents oligomeric BAK, i - interface of stacking and running gels and b - bottom of well.](figs4){#figs4}

![Insertion of Cysteines Does Not Affect Proapoptotic Function, Related to [Figure 5](#fig5){ref-type="fig"}\
Cysteine insertions were transiently transfected into DKO MEFs and 16 hr later cells were analyzed for apoptosis using Annexin V and PI staining. ^∗^p \< 0.05, from wt BAK, ND-not determined.](figs5){#figs5}

![Pre-Pore-to-Pore Conversion Is a Dynamic Process, Related to [Figure 6](#fig6){ref-type="fig"}\
(A) DKO MEFs were transfected with different concentrations of wt BAK R137C and V154C either alone or in the presence of zVAD-fmk (20 μM). After 24 hr, HM fractions were isolated and exposed to IASD and Western blotting used to detect labeled (L) and unlabeled (UL) species. CHAPS was used as a positive labeling control as described earlier.\
(B) BCL-X~L~ sequesters oligomerized BAK in the reconstitution system. HM fractions of untreated or ABT-737 treated, reconstituted HEK293T cells were exposed to CuPhe and lysed in 1% CHAPS. BCL-X~L~ was immunoprecipitated from lysates using FLAG M2 coated agarose beads. M~X~ - intramolecular disulphide linked monomeric BAK, M - monomeric BAK, D - dimer and D^X^ - oligomeric BAK.](figs6){#figs6}

![Schematic Representation of the Proposed Membrane Topologies of BAK, Related to [Figure 7](#fig7){ref-type="fig"}\
i) Membrane anchored pre-pore: Only the α9 helix, the transmembrane anchor, is inserted into the membrane. The pore domain is cytosolic, hence can be labeled by IASD. ii) Membrane inserted pre-pore: The pore domain is membrane inserted, hence IASD protected. The orientation of the pore domain in relation to the membrane plane remains speculative. Here a perpendicular arrangement is shown. iii) Membrane inserted pore: the pore domain spans the membrane and the polar surfaces of the largely amphipathic helices line the lumen of pore. This orientation results in the formation of an ion-conductive pore and as a consequence cysteines facing the pore lumen are labeled.](figs7){#figs7}
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